Lv1
80 积分 2023-03-21 加入
Engineering of Fc1 and Fc3 from human immunoglobulin G to analyse subclass specificity for staphylococcal protein A
7天前
已完结
A tool for analyzing complex epitope binning data of monoclonal antibodies
4个月前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
4个月前
已完结
Recent advances and impending challenges for the radiopharmaceutical sciences in oncology
4个月前
已完结
Living in LALA land? Forty years of attenuating Fc effector functions
6个月前
已完结
Living in LALA land? Forty years of attenuating Fc effector functions
7个月前
已完结
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
8个月前
已完结
VP4-2024: First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study
8个月前
已完结
Low-dose interleukin-2 therapy in autoimmune and inflammatory diseases: facts and hopes
9个月前
已完结
皖公网安备34019202002308
